Article
Oncology
Jinyang Hu, Feng Dong, You He, Xianyou Xia, Fangling Cheng, Sui Chen, Xiaoshuang Hou, Po Zhang, Guohao Liu, Ying Li, Qian Gao, Minhai Dong, Ting Li, Wei Li, Qungen Xiao, Xiaopeng Li, Xingjiang Yu, Guifa Xi, Dongsheng Guo, Xudong Wu, Baofeng Wang
Summary: This study reveals that GBM cells with high level LRIG2 can escape phagocytosis by tumor-associated microglia/macrophages, highlighting the potential of early clinical trials targeting LRIG2 and CD47-SIRP alpha as a novel treatment for GBM.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Johanna Erbani, Menno Boon, Leila Akkari
Summary: The interactions between tumor cells and their microenvironment are crucial for cancer progression and treatment response. This review focuses on the distinct microenvironmental niches in glioblastoma and their impact on therapy, particularly the interplay between tumor-associated macrophages and glioblastoma cells within different niches. Understanding the therapy-induced alterations in the glioblastoma microenvironment is essential for identifying targetable pathways and improving clinical outcomes through combination therapies.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Jun Ma, Clark C. Chen, Ming Li
Summary: The interaction between glioblastoma and its microenvironment, particularly involving tumor-associated macrophages and microglia, plays a crucial role in tumor development and treatment outcomes. Understanding the changes and functions of these cells may lead to new therapeutic approaches and improved prognosis for patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Sara Magri, Beatrice Musca, Camilla Bonaudo, Ada Tushe, Maria Giovanna Russo, Elena Masetto, Vittorina Zagonel, Giuseppe Lombardi, Alessandro Della Puppa, Susanna Mandruzzato
Summary: Glioblastoma (GBM) is a highly aggressive type of brain cancer with a challenging treatment landscape due to the immunosuppressive tumor microenvironment. This study reveals differences in immune profiles in central and marginal tumor areas, emphasizing the importance of understanding how treatments impact the immune composition for recurrence prevention. Detecting immune landscape changes in GBM relapses can aid in better stratification and treatment approaches.
Article
Cell Biology
Roberto Tamma, Giuseppe Ingravallo, Tiziana Annese, Antonio d'Amati, Loredana Lorusso, Domenico Ribatti
Summary: In this study, we analyzed biopsy specimens from adult patients with IDH1 wild type GBM and found that there was a significant increase in the number of total and M2 type macrophages, CD4(+)- and CD8(+)-lymphocytes, and CD34(+) microvessels in the tumor area compared to the healthy surrounding tissue. We also confirmed previous findings that there were higher numbers of p53 and BCL6(+) cells in the tumor area, with a positive correlation between BCL6 and CD34(+) microvessels. These results suggest that microenvironment components play an important role in GBM progression and could potentially be targeted for new therapies.
Review
Neurosciences
Matias Daniel Caverzan, Lucia Beauge, Paula Martina Oliveda, Bruno Cesca Gonzalez, Eugenia Micaela Buhler, Luis Exequiel Ibarra
Summary: Gliomas, specifically glioblastomas, are challenging to diagnose and treat. Monocytes, specifically tumor-associated macrophages (TAMs), play a significant role in tumor growth. TAMs represent a significant portion of the tumor mass in glioblastomas, and understanding their biology and functions can lead to therapeutic strategies for these tumors. This review focuses on the role of TAMs in tumor progression and resistance to treatment in glioblastomas.
Article
Biochemistry & Molecular Biology
Luiz Henrique Geraldo, Celina Garcia, Yunling Xu, Felipe Saceanu Leser, Izabella Grimaldi, Eduardo Sabino de Camargo Magalhaes, Joost Dejaegher, Lien Solie, Claudia Maria Pereira, Ana Helena Correia, Steven De Vleeschouwer, Bertrand Tavitian, Nathalie Henriques Silva Canedo, Thomas Mathivet, Jean-Leon Thomas, Anne Eichmann, Flavia Regina Souza Lima
Summary: The expression of C-C chemokine receptor type 7 (CCR7) and chemokine (C-C motif) ligand 21 (CCL21) are associated with poor survival in GBM patients. CCL21-CCR7 signaling regulates tumor cell migration and proliferation, as well as the recruitment of tumor-associated microglia/macrophages and VEGF-A production, which contributes to vascular dysmorphia. Inhibition of CCL21-CCR7 signaling increases sensitivity to temozolomide-induced tumor cell death, suggesting it as a potential therapeutic option against GBM.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Sarah E. Blitz, Ari D. Kappel, Florian A. Gessler, Neil V. Klinger, Omar Arnaout, Yi Lu, Pier Paolo Peruzzi, Timothy R. Smith, Ennio A. Chiocca, Gregory K. Friedman, Joshua D. Bernstock
Summary: Oncolytic virotherapy uses viruses to selectively infect malignant cells and stimulate antitumor response. The involvement of tumor-associated macrophage/microglia appears to play a crucial role in the failure of oncolytic virotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Beatrice Musca, Maria Giovanna Russo, Ada Tushe, Sara Magri, Greta Battaggia, Laura Pinton, Camilla Bonaudo, Alessandro Della Puppa, Susanna Mandruzzato
Summary: Brain metastases (BrM) and glioblastoma (GBM) exhibit differences in their immune profiles, with varying levels of immunosuppressive myeloid cells and lymphocytes lacking effector function. Understanding these differences is crucial for improving the efficacy of targeted immunotherapy strategies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Deyang Wu, Xiaowei Liu, Jingtian Mu, Jin Yang, Fanglong Wu, Hongmei Zhou
Summary: This article summarizes the important role of tumor-associated macrophages (TAMs) in tumor development, explores protein-dependent TAM target strategies, and discusses methods to manipulate TAMs to regulate the tumor microenvironment.
Article
Oncology
Alessandro Salvalaggio, Erica Silvestri, Giulio Sansone, Laura Pinton, Sara Magri, Chiara Briani, Mariagiulia Anglani, Giuseppe Lombardi, Vittorina Zagonel, Alessandro Della Puppa, Susanna Mandruzzato, Maurizio Corbetta, Alessandra Bertoldo
Summary: This study combines MRI with flow cytometry analysis to measure the infiltration of different leukocyte populations in glioblastoma (GBM) tumor tissues. The MRI features are significantly correlated with different myeloid cell populations, providing a potential new tool for investigating the microenvironment of GBM.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Anne Blank, Irina Kremenetskaia, Ruth M. Urbantat, Gueliz Acker, Kati Turkowski, Josefine Radke, Ulf C. Schneider, Peter Vajkoczy, Susan Brandenburg
Summary: The study identified two distinct myeloid cell populations in human glioblastoma, which play a role in tumor escape mechanisms by expressing alternative proangiogenic factors. Limited efficacy of anti-angiogenic therapy may be due to tumor-infiltrating myeloid cells bypassing VEGF-mediated pathways through expression of alternative proangiogenic factors.
JOURNAL OF PATHOLOGY
(2021)
Article
Oncology
Lingli Long, Yue Hu, Tengfei Long, Xiaofang Lu, Ying Tuo, Yubing Li, Zunfu Ke
Summary: This study revealed a positive relationship between the formation of OvCa-TAMs spheroids and the malignancy of OvCa cells, with M2-TAMs inducing the epithelial-mesenchymal transition of OvCa cells through the release of CCL18. The overexpression of ZEB1 in OvCa cells in ovarian mice models promoted the formation of OvCa-TAMs spheroids in ascites, leading to faster transcoelomic metastasis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Miranda W. Yu, Daniela F. Quail
Summary: Glioblastoma, a highly lethal brain cancer, has brought immunotherapy to the forefront of research, but faces challenges such as resistance, tumor heterogeneity, and immunosuppressive environments. Despite these difficulties, there is active pursuit of more effective immunotherapies for glioblastoma.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Lingyun Zhang, Yu Jiang, Gao Zhang, Shiyou Wei
Summary: This article explores the heterogeneity and plasticity of tumor-associated macrophages (TAMs) in recurrent glioblastoma (GBM) using single-cell technologies, and discusses the potential of TAM-targeted strategies for combination immunotherapy. It provides insights into the tumor microenvironment (TME) and the role of TAMs in promoting tumor growth, invasion, angiogenesis, immune suppression, and therapeutic resistance.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Clinical Neurology
Jijing Wang, Cong Guo, Zhaowei Meng, Marissa D. Zwan, Xin Chen, Sven Seelow, Susanna L. Lundstrom, Sergey Rodin, Charlotte E. Teunissen, Roman A. Zubarev
Summary: This study strengthens the association between isoAsp and Alzheimer's disease (AD) using novel approaches to isoAsp analysis in blood samples. The findings demonstrate elevated isoAsp levels, reduced anti-isoAsp antibodies, increased A beta concentration, and more protein aggregation in AD blood compared to controls. Additionally, deamidation reduces the binding capacity of blood protein HSA with A beta and p-tau.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Harald Hegen, Georgina Arrambide, Sharmilee Gnanapavan, Batia Kaplan, Michael Khalil, Ruba Saadeh, Charlotte Teunissen, Hayrettin Tumani, Luisa Maria Villar, Maria Alice Willrich, Henrik Zetterberg, Florian Deisenhammer
Summary: Cerebrospinal fluid (CSF) analysis is crucial for diagnosing and differentiating multiple sclerosis (MS) patients. Detection of CSF-restricted oligoclonal bands (OCBs) and kappa-free light chains (FLCs) proves the inflammatory nature of the disease and enhances diagnostic accuracy. Kappa-FLCs offer advantages such as fast, easy, cost-effective, reliable detection, and quantitative results, which can improve the prediction of MS disease activity. The international panel of experts recommends including intrathecal kappa-FLC synthesis in the next revision of MS diagnostic criteria.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Review
Clinical Neurology
Harald Hegen, Janette Walde, Klaus Berek, Georgina Arrambide, Sharmilee Gnanapavan, Batia Kaplan, Michael Khalil, Ruba Saadeh, Charlotte Teunissen, Hayrettin Tumani, Luisa M. Villar, Maria Alice Willrich, Henrik Zetterberg, Florian Deisenhammer
Summary: This study conducted a systematic review and meta-analysis to evaluate the diagnostic value of kappa-FLC index compared to OCB in identifying patients with CIS or MS, and to determine the cut-off for kappa-FLC index. The findings indicate that kappa-FLC index has similar diagnostic accuracy in MS as OCB.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Oncology
Ignacio Criado, Wendy G. Nieto, Guillermo Oliva-Ariza, Blanca Fuentes-Herrero, Cristina Teodosio, Quentin Lecrevisse, Antonio Lopez, Alfonso Romero, Julia Almeida, Alberto Orfao
Summary: Assessing the immune system in health and disease requires reference ranges, taking into consideration various factors. This study provides reference ranges for leukocyte populations in blood, based on the largest cohort to date, and highlights the immune profiles associated with low-count monoclonal B-cell lymphocytosis with a chronic-lymphocytic-leukemia-like phenotype (MBLlo).
Article
Clinical Neurology
Floor C. Loonstra, Lodewijk R. J. de Ruiter, Marleen J. A. Koel-Simmelink, Menno M. Schoonheim, Eva M. M. Strijbis, Bastiaan Moraal, Frederik Barkhof, Bernard M. J. Uitdehaag, Charlotte Teunissen, Joep Killestein
Summary: This study explores the association between novel blood biomarkers (sNfL, sGFAP, and sCNTN1) and disability outcome measures and MRI volumes in people with multiple sclerosis (MS). The results indicate that sNfL and sGFAP are associated with disease progression, while sCNTN1 is not related to clinical or MRI measures.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2023)
Article
Clinical Neurology
Jelle Y. Broos, Floor C. Loonstra, Lodewijk R. J. de Ruiter, Mariam Gouda, Wing Hee Fung, Menno M. Schoonheim, Marieke Heijink, Eva M. M. Strijbis, Charlotte Teunissen, Joep Killestein, Helga E. de Vries, Martin Giera, Bernard M. J. Uitdehaag, Gijs Kooij
Summary: This study investigated the association between bioactive lipid mediators (LMs) and clinical, biochemical, and MRI parameters in patients with multiple sclerosis (MS). The LM profiles of patients with progressive MS (PMS) were significantly different from those of patients with relapsing remitting MS (RRMS) and healthy controls (HCs), particularly with elevated levels of arachidonic acid (AA) derivatives. Specifically, 15-hydroxyeicosatetraenoic acid (HETE) was correlated with clinical and biochemical parameters and associated with neurodegenerative processes in PMS patients.
Article
Clinical Neurology
Maarten J. Mackenbach, Eline A. J. Willemse, Jan J. A. van den Dorpel, Nadine A. M. E. van der Beek, Jordi Diaz-Manera, Dimitris Rizopoulos, Charlotte Teunissen, Ans T. van der Ploeg, Johanna M. P. van den Hout
Summary: This study examines the association between neurofilament light (NfL) and central nervous system (CNS) involvement in patients with classic infantile Pompe disease. The results suggest that NfL levels may serve as a potential biomarker for assessing CNS damage in this population.
Article
Multidisciplinary Sciences
Dea Gogishvili, Eleonora M. Vromen, Sascha Koppes-den Hertog, Afina W. Lemstra, Yolande A. L. Pijnenburg, Pieter Jelle Visser, Betty M. Tijms, Marta Del Campo, Sanne Abeln, Charlotte E. Teunissen, Lisa Vermunt
Summary: This study used machine learning techniques to identify cerebrospinal fluid (CSF) biomarkers that predict the rate of cognitive decline in dementia patients. Longitudinal mini-mental state examination scores (MMSE) were used to create fast and slow progression groups. Random forest classifiers were trained on CSF proteomic profiles and a well-performing prediction model for the progression group was obtained. TNFRSF4 and TGF beta-1 emerged as the top markers for predicting cognitive decline.
SCIENTIFIC REPORTS
(2023)
Article
Clinical Neurology
Marie-Paule E. van Engelen, Hans Heijst, Eline A. J. Willemse, Mardien L. Oudega, Lisa Vermunt, Philip Scheltens, Everard G. B. Vijverberg, Yolande A. L. Pijnenburg, Charlotte E. Teunissen
Summary: The clinical overlap of frontotemporal dementia and primary psychiatric diseases makes diagnostic distinction difficult, leading to misdiagnosis and delay. Measurement of neurofilament light chain in urine is not suitable for differentiating frontotemporal dementia from psychiatric disorders, and serum neurofilament light chain remains the most patient-friendly matrix for differentiation.
BRAIN COMMUNICATIONS
(2023)
Article
Clinical Neurology
Lucia A. A. Giannini, Harro Seelaar, Emma L. van der Ende, Jackie M. Poos, Lize C. Jiskoot, Elise G. P. Dopper, Yolande A. L. Pijnenburg, Eline A. J. Willemse, Lisa Vermunt, Charlotte E. Teunissen, John C. van Swieten, Lieke H. Meeter
Summary: The increase in serum neurofilament light chain (NfL) levels can predict whether individuals with genetic frontotemporal dementia (FTD) are approaching the prodromal conversion stage. These findings provide important guidance for patient recruitment in clinical trials.
Article
Clinical Neurology
John J. Alam, Paul Maruff, Susan R. Doctrow, Hui-May Chu, Jennifer Conway, Stephen N. Gomperts, Charlotte Teunissen
Summary: This study evaluates the relationship between plasma tau phosphorylated at residue 181 (ptau181), a biomarker of Alzheimer disease (AD) copathology, and the treatment effects of the p38 alpha kinase inhibitor neflamapimod in patients with dementia with Lewy bodies (DLB). The results suggest that DLB patients with lower pretreatment ptau181 levels may show better treatment response to neflamapimod, with improvement in attention, cognitive assessment, and daily functioning. Plasma biomarkers of AD copathology should be considered as stratification variables in DLB clinical trials.
Article
Clinical Neurology
Yanaika S. S. Hok-A-Hin, Katharina Bolsewig, Daimy N. N. Ruiters, Alberto Lleo, Daniel Alcolea, Afina W. W. Lemstra, Wiesje M. M. van der Flier, Charlotte E. E. Teunissen, Marta del Campo
Summary: Our study showed that THOP1 can serve as an early specific biomarker for Alzheimer's Disease (AD). We developed THOP1 immunoassays and validated our findings in two independent cohorts.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2023)
Article
Cell Biology
Wiesje M. van der Flier, Marjolein E. de Vugt, Ellen M. A. Smets, Marco Blom, Charlotte E. Teunissen
Summary: Alzheimer's disease is a significant healthcare challenge with no current cure. This perspective proposes a strategy to shift the focus towards the pre-dementia stages and invest in personalized medicine for diagnosis, prediction and prevention. It suggests empowering patients and the public to actively participate in managing their health and disease, and developing improved strategies for early intervention.
Article
Medicine, Research & Experimental
Annieck M. Diks, Hans de Graaf, Cristina Teodosio, Rick J. Groenland, Bas de Mooij, Muktar Ibrahim, Alison R. Hill, Robert C. Read, Jacques J. M. van Dongen, Magdalena A. Berkowska
Summary: This study used high-dimensional flow cytometry to monitor the cellular responses to Bordetella pertussis challenge in the blood of 15 healthy donors. The results showed that individuals protected against colonization exhibited different early cellular responses compared to colonized individuals. These early cellular immune responses can be further characterized and potentially linked to an efficient mucosal immune response, ultimately evaluating the protective efficacy of new B. pertussis vaccine candidates.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
